Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay J Y, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner P A, Gelderblom H, Gokaslan Z L, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones R L, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum O J, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton K A, Timmermann B, Torri V, Tunn P U, Uhl M, Yamada Y, Weber D C, Vanel D, Varga P P, Vleggeert-Lankamp C L A, Casali P G, Sommer J
Departments of Cancer Medicine.
Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan.
Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054.
Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this group were published, covering the management of primary and metastatic chordomas. Additional evidence and further discussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF convened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recommendations of the first position paper.
脊索瘤是一种罕见的颅底和中轴骨骼恶性骨肿瘤。直到最近，专家们对于脊索瘤的适当临床管理尚未达成共识，导致许多患者的治疗不一致且预后不佳。为解决这一缺陷，欧洲医学肿瘤学会（ESMO）和全球脊索瘤患者倡导组织脊索瘤基金会召集了一个多学科的脊索瘤专家小组，以就脊索瘤的最佳治疗方法达成基于证据的共识性最佳实践。2015年1月，该小组的首批建议发表，涵盖原发性和转移性脊索瘤的管理。还需要更多证据和进一步讨论来制定关于局部区域复发治疗的建议。因此，ESMO和CF于2015年11月召开了第二次共识小组会议，以探讨局部复发脊索瘤的治疗。此次会议有来自欧洲、美国和日本的60多位在脊索瘤患者治疗方面具有专业知识的专家参与。该会议达成的共识是本出版物的主题，并补充了第一篇立场文件的建议。
